Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 189-194 , August 2002

Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy

  • Robert Dreicer

      Affiliations

    • Corresponding Author InformationCorrespondence to: Robert Dreicer, M.D., FACP, Cleveland Clinic Foundation, 9500 Euclid Ave R35, Cleveland, OH 44195, USA, Tel.: +1-216-445-4623; Fax: 1-216-445-2360

References 

  1. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309–1315
  2. Mettlin CJ, Murphy GP, Rosenthal DS, et al.  The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. Cancer. 1998;83:1679–1684
  3. Burkhardt JH, Litwin MS, Rose CM, et al.  Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J. Clin. Oncol. 2002;20:2869–2875
  4. Soulie M, Villers A, Grosclaude P, et al.  Cancer of the prostate in France: Results of the survey CCAFU–FRANCIM. Prog. Urol. 2001;11:478–485
  5. Amling CL, Blute ML, Bergstralh EJ, et al.  Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J. Urol. 2000;164:101–105
  6. Pound CR, Partin AW, Epstein JI, et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol. Clin. North Am. 1997;24:395–406
  7. Dillioglugil O, Leibman BD, Kattan MW, et al.  Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;50:93–97
  8. Savage P, Bates C, Abel P, et al.  British urological survey practice: 1. Prostate cancer. Br. J. Urol. 1997;79:754–755
  9. Laufer M, Pound CR, Carducci MA, et al.  Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology. 2000;55:309–315
  10. Walsh PC, Deweese TL, Eisenberger M. A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. J. Urol. 2001;166:508–516
  11. Sylvester J, Grimm P, Blasco J, et al.  The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the US. Urology. 2001;58:65–70
  12. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  13. Cher ML, Bianco FJ, Lam JS, et al.  Limited role of radionuclide bone scintigraphy in patients with prostate-specific antigen elevations after radical prostatectomy. J. Urol. 1998;160:1387–1391
  14. Kramer S, Gorich J, Gottfried HW, et al.  Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br. J. Radiol. 1997;70:995–999
  15. Kahn D, Williams RD, Seldin DW, et al.  Radioimmunoscintigraphy with 111indium-labeled Cyt-356 for the detection of occult prostate cancer recurrence. J. Urol. 1994;152:1490–1494
  16. Kahn D, Williams RD, Manyak MJ, et al.  111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J. Urol. 1998;159:2041–2046
  17. Hinkle GH, Burgers JK, Neal CE, et al.  Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111-capromab pendetide. Cancer. 1998;83:739–747
  18. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium-111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94:987–996
  19. Wasson JH, Fowler FJ, Barry MJ. Androgen-deprivation therapy for asymptomatic advanced prostate cancer in the prostate-specific antigen era: A national survey of urologist beliefs and practicies. J. Urol. 1998;159:1993–1997
  20. Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma: A reevaluation. Urology. 1973;1:553–560
  21. Byar DP. Proceedings: The Veterans Administration Co-operative Urological Research Group’s studies of cancer of the prostate. Cancer. 1973;32:1126–1130
  22. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997;337:295–300
  23. MV P, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of radiation therapy oncology group protocol 85-31. J. Clin. Oncol. 1997;15:1013–1021
  24. Pilepich MV, Winter K, John MJ, et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen-deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:1243–1252
  25. Messing EM, Manola J, Sarosdy M, et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999;341:1781–1789
  26. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate vs. deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–246
  27. Schroder FH. Endocrine treatments of prostate cancer: Recent developments and the future. Part I: Maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int. 1999;83:107–161
  28. Kirk D. RE: A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. J. Urol. 2002;167:651–652
  29. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Medical Research Council. Prostate cancer working party investigators group. BJU. 2000;(suppl 86):220
  30. Walsh PC, Deweese TL, Eisenberger M. RE: A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. Reply by authors. J. Urol. 2002;167:653
  31. Carroll PR, Lee KL, Fuks ZY, et al.  Cancer of the prostate. In:  Devita VT,  Hellman S,  Rosenberg SA editor. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins; 2001;p. 1463
  32. Daniell HW, Dunn SR, Ferguson DW, et al.  Progressive osteoporosis during androgen-deprivation therapy for prostate cancer. J. Urol. 2000;163:181–186
  33. Maillefert JF, Sibilia J, Michel F, et al.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 1999;161:1219–1222
  34. Hatano T, Oishi Y, Fututa A, et al.  Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. BJU Int. 2000;86:449–452
  35. Smith MR, Mcgovern FJ, Zietman AI, et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2001;345:948–955
  36. Herr HW, O’Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen-deprivation therapy. J. Urol. 2000;163:1743–1746
  37. Anderson J. Quality of life aspects of treatment options for localized and locally advanced prostate cancer. Eur. Urol. 2001;40:24–30
  38. Iversen P, Tyrrell CJ, Kaisary AV, et al.  Casodex (bicalutamide) 150mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998;51:389–396
  39. Tyrrell CJ, Kaisary AV, Iversen P, et al.  A randomised comparison of ’Casodex’ (bicalutamide) 150mg monotherapy vs. castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. 1998;33:447–456
  40. Seidenfeld J, Samson DJ, Hasselblad V, et al.  Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann. Intern. Med. 2000;132:566–577
  41. Dawson NA. Intermittent androgen deprivation. Curr. Oncol. Rep. 2000;2:409–416
  42. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem. Mol. Biol. 1990;37:843–847
  43. Furuya Y, Sato N, Akakura K, et al.  Paracrine growth stimulation of androgen-responsive Shionogi Carcinoma 115 by its autonomous subline (Chiba Subline 2). Cancer Res. 1990;50:4979–4983
  44. Gleave M, Bruchovsky N, Goldenberg SL, et al.  Intermittent androgen suppression for prostate cancer: Rationale and clinical experience. Eur. Urol. 1998;34:37–41
  45. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time of therapy. Oncologist. 2000;5:45–52
  46. Grossfeld GD, Chaudhary UB, Reese DM, et al.  Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001;58:240–245
  47. American Society For Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041
  48. Amling CL, Bergstralh EJ, Blute ML, et al.  Defining prostate-specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J. Urol. 2001;165:1146–1151
  49. Bubley GJ, Carducci M, Dahut W, et al.  Eligibility and response guidelines for phase II Clinical Trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J. Clin. Oncol. 1999;17:3461–3467
  50. Eisenberger MA, Nelson W. How much can we rely on the level of prostate-specific antigen as an end-point for evaluation of clinical trials? A word of caution. J. Natl. Cancer Inst. 1996;88:779–781
  51. Goluboff ET, Prager D, Rukstalis D, et al.  Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 2001;166:882–886

PII: S0305-7372(02)00046-4

Cancer Treatment Reviews
Volume 28, Issue 4 , Pages 189-194 , August 2002

Article Tools